SABR pre-treatment checks using alanine and nanoDot dosimeters

Stereotactic Ablative Radiotherapy (SABR) remains one of the preferred treatment techniques for early-stage cancer. It can be extended to more treatment locales involving the sternum, scapula and spine. This work investigates SABR checks using Alanine and nanoDot dosimeter for three treatment sites, including sternum, spine and scapula. Alanine and nanoDot dosimeters’ performances were verified using a 6 MV photon beam before SABR pretreatment verifications. Each dosimeter was placed inside customized designed inserts into a Rod Phantom (in-house phantom) made of Perspex that mimics the human body for a SABR check. Electron Paramagnetic Resonance (EPR) spectrometer, Bruker EleXsys E500 (9.5 GHz) and Microstar (Landauer Inc.) Reader was employed to acquire the irradiated alanine and nanoDot dosimeters’ signal, respectively. Both dosimeters treatment sites are expressed as mean ± standard deviation (SD) of the measured and Eclipse calculated dose Alanine (19.59 ± 0.24, 17.98 ± 0.15, 17.95 ± 0.18) and nanoDot (19.70 ± 0.43, 17.05 ± 0.08, 17.95 ± 0.98) for spine, scapula and sternum, respectively. The percentage difference between alanine and nanoDot dosimeters was within 2% for sternum and scapula but 2.4% for spine cases. These results demonstrate Alanine and nanoDot dosimeters’ potential usefulness for SABR pretreatment quality assurance (QA).